Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma

Summary

The investigators reported previously that epigenetic activation of organic cation transporter (OCT2) by decitabine sensitizes RCC cells to oxaliplatin both in vitro and in xenografts. The objective of this phase II clinical trial is to investigate the efficacy and safety of sequential combination therapy with decitabine and oxaliplatin in patients with relapsed/metastatic renal cell carcinoma who progressed on standard of care.

Timeline

Start

2019-08-15

Primary completion

2021-06-30

Completion

2021-12-31

Drugs

Indications